Cabaletta Bio, co-founded by Aimee Payne, MD, PhD, former Penn Medicine faculty member, and Michael Milone, MD, PhD, Associate Professor of Pathology and Laboratory Medicine at Penn Medicine, reported encouraging clinical data for its CAR T-cell therapy, RESE-CEL™, across multiple autoimmune diseases. The company is targeting an FDA submission for approval in the second half of 2027. Read more here.